Estrogens and glucocorticoids have opposing effects on the amount and latent activity of complement proteins in the rat uterus

Biology of Reproduction

Volumn 74, Issue 2, 2006, Pages 265-274

  Rhen, Turk ^a,b   Cidlowski, John A ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b UNIVERSITY OF NORTH DAKOTA   (United States)

Author keywords

Complement; Estradiol; Female reproductive tract; Immunology; Inflammation; Reproductive immunology; Rodent; Steroid hormones; Uterus

Indexed keywords

BRADYKININ B1 RECEPTOR; COMPLEMENT; DEXAMETHASONE; ESTRADIOL; ESTROGEN; GLUCOCORTICOID; PROTEIN; STEROID HORMONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERICIDAL ACTIVITY; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; EXTRAVASATION; FEMALE; FETOPLACENTAL UNIT; GENITAL SYSTEM; HOST RESISTANCE; IMMUNE SYSTEM; IMMUNOMODULATION; IN VITRO STUDY; MAMMAL; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; REGULATORY MECHANISM; UTERUS; VASODILATATION;

ANIMALS; BODY FLUIDS; BRADYKININ; COMPLEMENT C1 INACTIVATOR PROTEINS; COMPLEMENT SYSTEM PROTEINS; DEXAMETHASONE; ESCHERICHIA COLI; ESTRADIOL; ESTROGENS; FEMALE; GLUCOCORTICOIDS; POLYMERASE CHAIN REACTION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, BRADYKININ B1; SERPINS; UTERUS;

ANIMALIA; MAMMALIA; RODENTIA;

EID: 31044452505     PISSN: 00063363     EISSN: None     Source Type: Journal    
DOI: 10.1095/biolreprod.105.045336     Document Type: Article

References (62)

1. Carroll MC, Prodeus AP. Linkages of innate and adaptive immunity. Curr Opin Immunol 1998; 10:36-40.
2. Barrington R, Zhang M, Fischer M, Carroll MC. The role of complement in inflammation and adaptive immunity. Immunol Rev 2001; 180:5-15.
3. Caucheteux SM, Kanellopoulos-Langevin C, Ojcius DM. At the innate frontiers between mother and fetus: linking abortion with complement activation. Immunity 2003; 18:169-172.
4. Xu C, Mao D, Holers VM, Palanca B, Cheng AM, Molina H. A critical role for murine complement regulator CRRY in fetomaternal tolerance. Science 2000; 287:498-501.
5. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998; 281:1191-1193.
6. Mellor AL, Sivakumar J, Chandler P, Smith K, Molina H, Mao D, Munn DH. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol 2001; 2:64-68.
7. Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, Espinola R, Xiaowei LE, Mao D, Vialpando CG, Salmon JE. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195:211-220.
8. Kuivanen PC, Capulong RB, Harkins RN, DeSombre ER. The estrogen-responsive 110K and 74K rat uterine secretory proteins are structurally related to complement component C3. Biochem Biophys Res Commun 1989; 158:898-905.
9. Sundstrom SA, Komm BS, Ponce-de-Leon H, Yi Z, Teuscher C, Lyttle CR. Estrogen regulation of tissue-specific expression of complement C3. J Biol Chem 1989; 264:16941-16947.
10. Hasty LA, Brockman WW, Lambris JD, Lyttle CR. Hormonal regulation of complement factor B in human endometrium. Am J Reprod Immunol 1993; 30:63-67.
11. Li SH, Huang HL, Chen YH. Ovarian steroid-regulated synthesis and secretion of complement C3 and factor B in mouse endometrium during the natural estrous cycle and pregnancy period. Biol Reprod 2002; 66:322-332.
12. Nishikawa Y, Baba T, Imori T. Effect of the estrous cycle on uterine infection induced by Escherichia coli. Infect Immun 1984; 43:678-683.
13. Nishikawa Y, Baba T. Effects of ovarian hormones on manifestation of purulent endometritis in rat uteruses infected with Escherichia coli. Infect Immun 1985; 47:311-317.
14. Nishikawa Y, Baba T. In vitro adherence of Escherichia coli to endometrial epithelial cells of rats and influence of estradiol. Infect Immun 1985; 50:506-509.
15. Kaushic C, Zhou F, Murdin AD, Wira CR. Effects of estradiol and progesterone on susceptibility and early immune responses to Chlamydia trachomatis infection in the female reproductive tract. Infect Immun 2000; 68:4207-4216.
16. Sonnex C. Influence of ovarian hormones on urogenital infection. Sex Transm Infect 1998; 74:11-19.
17. Rakasz E, Lynch RG. Female sex hormones as regulatory factors in the vaginal immune compartment. Int Rev Immunol 2002; 21:497-513.
18. Cramer DW, Wise LA. The epidemiology of recurrent pregnancy loss. Semin Reprod Med 2000; 18:331-339.
19. Quentin R, Lansac J. Pelvic inflammatory disease: medical treatment. Eur J Obstet Gynecol Reprod Biol 2000; 92:189-192.
20. Locksmith G, Duff P. Infection, antibiotics, and preterm delivery. Semin Perinatol 2001; 25:295-309.
21. Wira CR, Fahey JV. The innate immune system: gatekeeper to the female reproductive tract. Immunology 2004; 111:13-15.
22. Sacks G, Sargent I, Redman C. An innate view of human pregnancy, Immunol Today 1999; 20:114-118.
23. Mellor AL, Munn DH. Immunology at the maternal-fetal interface: lessons for T cell tolerance and suppression. Annu Rev Immunol 2000; 18:367-391.
24. Erlebacher A. Why isn't the fetus rejected? Curr Opin Immunol 2001; 13:590-593.
25. Rhen T, Grissom S, Afshari C, Cidlowski JA. Dexamethasone blocks the rapid biological effects of 17 beta-estradiol in the rat uterus without antagonizing its global genomic actions. FASEB J 2003; 17:1849-1870.
26. Gibbs RB. Fluctuations in relative levels of choline acetyltransferase mRNA in different regions of the rat basal forebrain across the estrous cycle: effects of estrogen and progesterone. J Neurosci 1996; 16:1049-1055.
27. Owens JW, Ashby J. Critical review and evaluation of the uterotrophic bioassay for the identification of possible estrogen agonists and antagonists: in support of the validation of the OECD uterotrophic protocols for the laboratory rodent. Organisation for Economic Cooperation and Development. Crit Rev Toxicol 2002; 32:445-520.
28. McKay LI, Cidlowski JA. Corticosteroids. In: Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E, (eds.), Cancer Medicine. London: B. C. Decker Inc; 2000:730-742.
29. Green TP, Johnson DE, Marchessault RP, Gatto CW. Transvascular flux and tissue accrual of Evans blue: effects of endotoxin and histamine. J Lab Clin Med 1988; 111:173-183.
30. Peng X, Hassoun PM, Sammani S, McVerry BJ, Burne MJ, Rabb H, Pearse D, Tuder RM, Garcia JG. 2004. Protective effects of sphingosine 1 - phosphate in murine endotoxin-induced inflammatory lung injury. Am J Respir Crit Care Med 2004; 169:1245-1251.
31. Kirschfink M, Nurnberger W. C1 inhibitor in anti-inflammatory therapy: from animal experiment to clinical application. Mol Immunol 1999; 36:225-232.
32. Weisman HF, Bartow T, Leppo MK, Marsh HC Jr, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990; 249:146-151.
33. Chai PJ, Nassar R, Oakeley AE, Craig DM, Quick G Jr, Jaggers J, Sanders SP, Ungerleider RM, Anderson PA. Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage. Circulation 2000; 101:541-546.
34. Howe RS, Lee YH, Fischkoff SA, Teuscher C, Lyttle CR. Glucocorticoid and progestin regulation of eosinophil chemotactic factor and complement C3 in the estrogen-treated rat uterus. Endocrinology 1990; 126:3193-3199.
35. Lundeen SG, Zhang Z, Zhu Y, Carver JM, Winneker RC. Rat uterine complement C3 expression as a model for progesterone receptor modulators: characterization of the new progestin trimegestone. J Steroid Biochem Mol Biol 2001; 78:137-143.
36. Vogel CW, Muller-Eberhard HJ. The cobra venom factor-dependent C3 convertase of human complement. A kinetic and thermodynamic analysis of a protease acting on its natural high molecular weight substrate. J Biol Chem 1982; 257:8292-8299.
37. Beagley KW, Gockel CM. Regulation of innate and adaptive immunity by the female sex hormones oeslradiol and progesterone. FEMS Immunol Med Microbiol 2003; 38:13-22.
38. Maslow AS, Davis CH, Choong J, Wyrick PB. Estrogen enhances attachment of Chlamydia trachomatis to human endometrial epithelial cells in vitro. Am J Obstet Gynecol 1988; 159:1006-1014.
39. Louv WC, Austin H, Perlman J, Alexander WJ. Oral contraceptive use and the risk of chlamydial and gonococcal infections. Am J Obstet Gynecol 1989; 160:396-402.
40. Rank RG, Sanders MM, Kidd AT. Influence of the estrous cycle on the development of upper genital tract pathology as a result of chlamydial infection in the guinea pig model of pelvic inflammatory disease. Am J Pathol 1993; 142:1291-1296.
41. Sweet RL, Btankfort-Doyle M, Robbie MO, Schacter J. The occurrence of chlamydial and gonococcal salpingilis during the menstrual cycle. JAMA 1986; 255:2062-2064.
42. Stoiber H, Kacani L, Speth C, Wurzner R, Dierich MP. The supportive role of complement in HIV pathogenesis. Immunol Rev 2001; 180:168-176.
43. Edwards JL, Brown EJ, Ault KA, Apicella MA. The role of complement receptor 3 (CR3) in Neisseria gonorrhoeae infection of human cervical epithelia. Cell Microbiol 2001, 3:611-622.
44. Edwards JL, Brown EJ, Uk-Nham S, Cannon JG, Blake MS, Apicella MA. A co-operalive interaction between Neisseria gonorrhoeas and complement receptor 3 mediates infection of primary cervical epithelial cells. Cell Microbiol 2002; 4:571-584.
45. Taylor-Robinson D, Furr PM, Hetherington CM. Neisseria gonorrhoeas colonises the genital tract of oestradiol-treated germ-free female mice. Microb Pathol 1990; 9:369-373.
46. Nowicki S, Selvarangan R, Anderson G. Experimental transmission of Neisseria gonorrhoeas from pregnant rat to fetus. Infect Immun 1999; 67:4974-4976.
47. Nguyen D. Gonorrhea in pregnancy and in the newborn. Am Fam Physician 1984; 29:185-189.
48. Hasty LA, Lambris JD, Lessey BA, Pruksananonda K, Lyttle CR. Hormonal regulation of complement components and receptors throughout the menstrual cycle. Am J Obstet Gynecol 1994; 170:168-175.
49. Young SL, Lessey BA, Fritz MA, Meyer WR, Murray MJ, Speckman PL, Nowicki BJ. In vivo and in vitro evidence suggest that HB-EGF regulates endometrial expression of human decay-accelerating factor. J Clin Endocrinol Metab 2002; 87:1368-1375.
50. Iborra A, Mayorga M, Llobet N, Martinez P. Expression of complement regulatory proteins [membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59)] in endometrial stressed cells. Cell Immunol 2003; 223:46-51.
51. Hewiit SC, Deroo BJ, Hansen K, Collins J, Grissom S, Afshari CA, Korach KS. Estrogen receptor-dependent genomic responses in the uterus mirror the biphasic physiological response to estrogen. Mol Endocrinol 2003; 17:2070-2083.
52. Lippe BM, Szego CM. Participation of adrenocortical hyperactivity in the suppressive effect of systemic actinomyein D on uterine stimulation by oestrogen. Nature 1965; 207:272-274.
53. Velardo JT, Hisaw FL, Bever AT. Inhibitory action of desoxycorticosterone acetate, cortisone acetate, and testosterone on uterine growth induced by estradiol-17β. Endocrinology 1956; 59:165-169.
54. Bitman J, Cecil HC. Differential inhibition by Cortisol of estrogen-stimulated uterine responses. Endocrinology 1967; 80:423-429.
55. Bigsby RM. Progesterone and dexamethasone inhibition of estrogen-induced synthesis of DNA and complement in rat uterine epithelium: effects of antiprogesterone compounds. J Steroid Biochem Mol Biol 1993; 45:295.
56. Resnik R. The endocrine regulation of uterine blood How in the nonpregnant uterus: a review. Am J Obstet Gynecol 1981; 140:151-156.
57. Sarrel PM. The differential effects of oestrogens and progestins on vascular tone. Hum Reprod Update 1999; 5:205-209.
58. Whitworth JA, Schyvens CG, Zhang Y, Mangos GJ, Kelly JJ. Glucocorticoid-induced hypertension: from mouse to man. Clin Exp Pharmacol Physiol 2001; 28:993-996.
59. McLean PG, Perretti M, Ahluwalia A. Kinin B(1) receptors and the cardiovascular system: regulation of expression and function. Cardiovasc Res 2000; 48:194-210.
60. Bian Z, Nilsson S, Gustafsson JA. Selective estrogen receptor modulators and coronary heart disease. Trends Cardiovasc Med 2001; 11:196-202.
61. Haeger M. The role of complement in pregnancy-induced hypertensive disease. Int J Gynaecol Obstet 1993; 43:113-127.
62. Martin JN Jr, Thigpen BD, Rose CH, Cushman J, Moore A, May WL. Maternal benefit of high-dose intravenous corticosteroid therapy for HELLP syndrome. Am J Obstet Gynecol 2003; 189:830-834.